TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma Clinical Trial

Official title:

Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03123393
• Other study ID #: C34004
• Secondary ID: U1111-1187-62082
• Status: Terminated
• Phase: Phase 2
• Start date: October 10, 2017
• Est. completion date: December 17, 2019

Study information

• Verified date: February 2023
• Source: Calithera Biosciences, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed or refractory DLBCL.

Description:

The drug being tested is TAK-659. This study will evaluate overall response rate (ORR) in participants with relapsed or refractory DLBCL who take TAK-659.

The study will enroll approximately 122 participants. Participants will be assigned to:

• TAK-659 60 mg to 100 mg

All participants will be asked to take the tablets of TAK-659 at the same time each day throughout the study in a 28-day cycle.

This multi-center trial will be conducted in the United States, United Kingdom, Spain, Italy, France, Canada, Germany. The overall time to participate in this study is approximately 48 months. Participants will be assessed for disease response and progression during the PFS follow-up every 3 months after end of treatment (for participants who discontinue due to reasons other than disease progression) and OS follow-up every 3 months from the last dose of study drug until death or conclusion of the study, whichever occurs first.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 49
• Est. completion date: December 17, 2019
• Est. primary completion date: December 17, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Must have histologically confirmed DLBCL, including de novo disease or transformed disease from indolent NHL.

a. High-grade B-cell lymphoma (BCL) with MYC and BCL-2 and/or BCL-6 translocations (double-hit DLBCL under DLBCL, not otherwise specified [NOS], based on the 2008 World Health Organization [WHO] classification criteria) is not eligible for this study.

2. Local pathology review for histological confirmation; A formalin-fixed, paraffin-embedded (FFPE) tumor block or appropriately stained slides from a fresh biopsy is required.

3. Relapsed or refractory to greater than or equal to (>=) 2 prior lines of chemotherapy based on standard of care with certain requirements for prior therapy.

4. Documented investigator-assessed relapse or progression after the last treatment is required if the participant responded and then progressed on the prior treatment.

5. Measurable disease per IWG 2007 criteria.

6. Eastern Cooperative Oncology Group (ECOG) performance status less than (<) 2.

7. Life expectancy of greater than (>) 3 months.

8. Adequate organ function, including the following:

1. Bone marrow reserve: absolute neutrophil count (ANC) >=1000/microliter (µL), platelet count >=75,000/µL (>=50,000/µL for participants with bone marrow involvement), and hemoglobin >=8 gram per deciliter (g/dL).

2. Hepatic: total bilirubin less than or equal to (<=) 1.5 times the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=2.5*ULN.

3. Renal: creatinine clearance >=60 milliliter per minute (mL/min).

4. Others:

• Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.

• Blood pressure <=Grade 1 (hypertensive participants are permitted if their blood pressure is controlled to <=Grade 1 by hypertensive medications.

• Glycosylated hemoglobin is <=6.5% hyperglycemic participants permitted if glucose is well controlled by antihyperglycemic medication).

Exclusion Criteria:

1. Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases.

2. Known human immunodeficiency virus (HIV)-related malignancy.

3. Systemic anticancer treatment (including investigational agents) less than 3 weeks before the first dose of study treatment (<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agents; <=8 weeks for cell-based therapy or anti-tumor vaccine).

4. Radiotherapy less than 3 weeks before the first dose of study treatment. If prior radiotherapy occurred <4 to 6 weeks before study start, as radiated lesions cannot be reliably assessed by fluorodeoxyglucose-positron emission tomography (FDG-PET), nonradiated target lesions are required for eligibility, and prior radiotherapy information must be submitted to the IRC.

5. Known HIV positive, hepatitis B surface antigen positive or known or suspected active hepatitis C infection.

6. Prior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time without full hematopoietic recovery before Cycle 1 Day 1, or allogeneic stem cell transplant any time.

7. Participants with certain cardiovascular conditions are excluded.

8. Major surgery within 14 days before the first dose of study drug or incomplete recovery from any complications from surgery.

9. Systemic infection requiring parenteral antibiotic therapy or other serious infection (bacterial, fungal, or viral) within 21 days before the first dose of study drug.

10. Treatment with high-dose corticosteroids for anticancer purposes within 7 days before the first dose of TAK-659.

11. Participants with another malignancy within 2 years of study start. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.

12. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659.

13. Received medications, supplements, or food/beverages that are P-glycoprotein (P-gp) inhibitors or inducers or strong cytochrome P450 (CYP) 3A inhibitors or inducers within a certain timeframe prior to the first dose of study drug. Depending on the substance, the washout period for P-gp inhibitors or inducers or strong CYP3A inhibitors or inducers will be either 7 days or 5 times the half-life (half-life is related to the time required for elimination from the body). The washout period for grapefruit containing food or beverages is 5 days.

Related Conditions & MeSH terms

• Diffuse Large B-cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• TAK-659
TAK-659 Tablets

Locations

Country	Name	City	State
Canada	CHU de Quebec -Universite Laval-Hopital de L'Enfant Jesus	Quebec
Canada	Centre Hospitalier Regional de Rimouski	Rimouski	Quebec
Canada	Princess Margaret Cancer Center	Toronto	Ontario
France	CHRU Clermont- Ferrand CHU Estaing	Clermont-Ferrand	Auvergne
France	Hopital Dupuytren	Limoges Cedex	Limousin, Lorraine
France	Institut Paoli Calmettes Departement de Recherche Clinique et de l'Innovation	Marseille	Provence Alpes COTE D'azur
France	Hopital Necker-Enfants Malades	Paris	Ile-de-france
France	Hopital Saint Louis	Paris Cedex 10	Ile-de-france
France	Groupe Hospitalier - Hopitaux Universitaires Pitie-Salpetriere - Charles-Foix - Pitie-Salpetriere	Paris Cedex 13	Ile-de-france
France	Hopital Haut-Leveque	Pessac Cedex	Aquitaine
France	Centre Hospitalier Lyon Sud	Pierre Benite Cedex	Rhone-alpes
France	Centre Henri-Becquerel	Rouen Cedex 1	Haute-normandie
France	Institut Gustave Roussy	Villejuif Cedex	Ile-de-france
Italy	Azienda Ospedaliera Papa Giovanni XXIII	Bergamo
Italy	Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda	Milano
Italy	Azienda Ospedaliero-Universitaria "Maggiore della Carita"	Novara
Italy	Ospedale Casa Sollievo della Sofferenza	San Giovanni Rotondo	Foggia
Italy	Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino	Torino	Piemonte
Italy	Azienda Ospedaliero Universitaria Santa Maria della Misericordia di Udine	Udine
Spain	Hospital Clinic de Barcelona	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital General Universitario Gregorio Maranon	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario de Salamanca	Salamanca
Spain	Hospital Universitario Marques de Valdecilla	Santander
Spain	Hospital Universitario La Fe	Valencia
United Kingdom	University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital	Birmingham	England
United Kingdom	London North West Healthcare NHS Trust, Imperial College London	Harrow	England
United Kingdom	University College London Hospitals NHS Foundation Trust	London	England
United Kingdom	The Christie NHS Foundation Trust	Manchester	England
United Kingdom	Newcastle Hospitals NHS Foundation Trust	Newcastle upon Tyne	England
United States	University of Michigan	Ann Arbor	Michigan
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Swedish Medical Oncology - Edmonds	Edmonds	Washington
United States	Swedish Cancer Institute - Issaquah	Issaquah	Washington
United States	New York University Langone Medical Center	New York	New York
United States	Perelman Center for Advanced Medicine	Philadelphia	Pennsylvania
United States	Swedish First Hill Campus	Seattle	Washington
United States	Swedish Health Services	Seattle	Washington
United States	University of Washington, Hutchinson Cancer Research Center	Seattle	Washington
United States	University of Kansas Medical Center	Westwood	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Calithera Biosciences, Inc

Countries where clinical trial is conducted

United States,  Canada,  France,  Italy,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stage 2: ORR as Assessed by Independent Radiologic Review Committee (IRRC) Based on Modified 2007 International Working Group (IWG) Criteria	ORR was defined as the percentage of participants with complete response (CR), or partial response (PR) as assessed by IRRC according to the modified 2007 IWG criteria for malignant lymphoma. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.	Up to 12 months
Secondary	Stage 2: CR Rate as Assessed by IRC Based on Modified 2007 IWG Criteria	CR rate was defined as percentage of participants with complete response as assessed by IRC according to the modified 2007 IWG. CR was defined as disappearance of all evidence of disease.	Up to 12 months
Secondary	Stage 2: ORR as Assessed by IRRC Based on 2014 IWG-Lugano Criteria	ORR was defined as the percentage of participants with CR or PR as assessed by IRRC according to the 2014 Lugano classification, IWG criteria for malignant lymphoma. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.	Up to 12 months
Secondary	Stage 2: CR Rate as Assessed by IRRC Based on 2014 IWG-Lugano Criteria	CR rate was defined as percentage of participants with complete response as assessed by IRC according to the 2014 Lugano classification, IWG criteria. CR was defined as disappearance of all evidence of disease.	Up to 12 months
Secondary	Stage 2: Duration of Response (DOR)	DOR was defined as the time from the date of first documentation of a CR/PR to the date of first documentation of tumor progression or progressive disease (PD) per IRRC assessment according to IWG criteria. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites. PD was defined as presence of any new lesion or increase by >=50% of previously involved sites from nadir.	Up to 12 months
Secondary	Stage 2: Duration of CR	Duration of CR was defined as the time from the date of first documentation of a CR/PR to the date of first documentation of tumor progression or PD per IRRC assessment according to IWG criteria. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites. PD was defined as presence of any new lesion or increase by >=50% of previously involved sites from nadir.	Up to 12 months
Secondary	Stage 2: ORR as Assessed by IRRC in Participants With Germinal Center B-cell (GCB) DLBCL	ORR was defined as the percentage of participants with CR or PR as assessed by IRRC according to the modified 2007 IWG criteria for malignant lymphoma. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.	Up to 12 months
Secondary	Stage 2: ORR as Assessed by IRC in Participants With DLBCL Transformed From Indolent Non-Hodgkin's Lymphoma (NHL)	ORR was defined as the percentage of participants with CR or PR as assessed by IRC according to the modified 2007 IWG criteria for malignant lymphoma. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.	Up to 12 months
Secondary	Stage 2: Progression Free Survival (PFS) as Assessed by IRC	PFS was defined as time from start of study treatment to first documentation of PD per IRC assessment or up to death due to any cause, whichever occurs first based on IWG criteria. PD was defined as presence of any new lesion or increase by >=50% of previously involved sites from nadir.	Up to 18 months
Secondary	Stage 2: Overall Survival (OS)	OS was defined as the time from start of study treatment to date of death due to any cause.	Up to 24 months
Secondary	Stage 1: ORR as Assessed by IRRC to Select Stage 2 Dose Regimen of TAK-659 From the Lead-in Dose Exploration Phase	ORR was defined as the percentage of participants with CR or PR as assessed by IRC. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.	Up to 12 months
Secondary	Stage 2: ORR as Assessed by IRC at 3, 6, and 9 Cycles in Participants With DLBCL	ORR was defined as the percentage of participants with CR or PR as assessed by IRC according to the modified 2007 IWG criteria for malignant lymphoma. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.	At Cycles 3, 6 and 9 (Up to 12 months) (Each cycle of 28 days)